Looking back at April’s data digging and analysis
Using EvaluatePharma data, Vantage has described how big pharma R&D spending has shifted, showed how internally discovered novel medicines account for a growing…
Corporate VC activity in medtech increases – until this year
In 2018 more than a quarter of medtech funding came from rounds in which corporate VCs took part.
A Nasdaq float is scrapped, but for Poseida that’s great news
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Venture funding slowdown continues in first quarter of 2019
Venture funding drops again, but there’s no need to panic yet.
Auris acquisition could prompt more mega VC rounds
The J&J-Auris tie-up will yield a huge return for investors who went in big.
Are the big corporate venture arms retreating?
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.
Deals galore for a new generation of transcatheter mitral valves
Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.
Biopharma's record venture year ends with a slowdown
Venture capital firms invested a record $16.8bn in private drug developers globally in 2018, but signs of a cooling are clear.
Fewer than 200 medtech VC rounds closed in 2018
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.